NK4 or adenovirus vector expressing NK4 (Ad-NK4) can act bifunctionally as a hepatocyte growth factor antagonist and angiogenesis inhibitor and has potential value in cancer therapy. The aim of this study was to evaluate the therapeutic efficacy of Ad-NK4 in combination with gemcitabine (GEM) against pancreatic cancer. In vitro study showed a strong antiproliferative effect of GEM and a potent anti-invasive effect of Ad-NK4 against pancreatic cancer cells. In in vivo experiments, SUIT-2 human pancreatic cancer cells were implanted into the pancreas of nude mice. Mice were treated with Ad-NK4 by injection into the peritumoral region of the pancreas on day 5 after implantation followed by weekly i.p. injections of GEM. On day 28 after implantation, pancreatic tumor volume was significantly smaller than that in mice treated with Ad-LacZ, Ad-NK4 alone, or GEM alone. Furthermore, combination therapy completely suppressed peritoneal dissemination and liver metastases, leading to significantly increased survival. Histologic and immunohistochemical assays of primary tumors indicated that combination therapy prohibited both cell proliferation and angiogenesis, resulting in high levels of apoptosis. These results suggest that peritumoral injection of Ad-NK4 plus GEM is a potent combination therapy for pancreatic cancer.
Introduction
Pancreatic cancer possesses the potential for strong growth and metastasis and is one of the most fatal human cancers. In Japan, it has been estimated that this disease causes 19 000 deaths per year; the number has increased 2.5-fold in the past 20 years. 1 Despite developments in diagnostic imaging, the majority of patients with pancreatic cancer are diagnosed at the advanced stage of the disease and show an overall 5-year survival rate of only 1-4%. 2 Most patients treated by curative resection develop incurable local relapse, liver metastases, and/or peritoneal dissemination. Conventional adjuvant therapy such as radiation, chemotherapy, immunotherapy, or a combination of these, has little beneficial effect on this aggressive neoplasm. Among the limited chemotherapeutic agents available, gemcitabine (GEM), a new deoxycytidine analogue, has become the first-line treatment for pancreatic cancer. 3 Intracellularly phosphorylated GEM interacts directly with DNA and potently inhibits the proliferation of pancreatic cancer cells. However, the survival benefit of GEM for advanced pancreatic cancer remains limited.
Hepatocyte growth factor (HGF) was identified first as a potent mitogen for hepatocytes, 4, 5 however, a distinct role of HGF in cancer development via tumor-stromal interactions has been identified. [6] [7] [8] In pancreatic cancer, fibroblast-derived HGF mainly confers mitogenic potential by binding to the c-Met receptor, 9, 10 which is frequently overexpressed in this cancer, but displays minimal mitogenic activity. 7, 11, 12 Phosphorylated c-Met receptor accelerates the migratory and invasive ability of pancreatic cancer via MAP kinase activation. 13, 14 Furthermore, increased mRNA and protein levels of c-Met and/or HGF have been frequently reported in human pancreatic carcinoma in contrast to weak expression in normal tissue. 11, 15, 16 Additionally, high levels of HGF have been reported in peritoneal fluid after pancreatic cancer surgery, and ascitic fluid strongly stimulates the invasive ability of pancreatic cancer cells. 7 Thus, HGF and c-Met receptor may be involved in the malignant behavior of pancreatic cancer, and prevention of the HGF-c-Met association may be of considerable therapeutic value.
We developed NK4, a synthetic competitive antagonist of HGF, which comprises the N-terminal hairpin domain and subsequent four kringle domains of the HGFa subunit. 6, 17, 18 NK4 binds competitively to the c-Met receptor and abrogates the accelerated motility induced by HGF. Additionally, NK4 exerts an antiangiogenic effect independent of its activity as an HGF antagonist. 19 NK4 may be of value in cancer therapy by targeting the malignant behavior of cancer cells rather than by killing the cells directly. We reported that, in vitro, recombinant NK4 or adenovirus vector-expressing NK4 (Ad-NK4) inhibits spreading and invasion of human pancreatic cancer cells 7 and, in vivo, suppresses growth, invasion, and metastasis of human pancreatic cancer cells orthotopically implanted into nude mice. 8 Hence, gene therapy with Ad-NK4 may be an effective cytostatic treatment to prohibit motility and angiogenesis of pancreatic cancer.
Combination treatment with Ad-NK4 plus GEM may provide an optimal therapy for controlling pancreatic cancer. In the present study, we analyzed the therapeutic efficacy of Ad-NK4 in combination with GEM against pancreatic cancer in vitro and in vivo. In vitro results indicated that GEM exerts a strong antiproliferative effect but is relatively ineffective against the invasive ability of pancreatic cancer. In contrast, Ad-NK4 exerted no antiproliferative effect but did show a potent anti-invasive effect. In vivo experiments indicated that peritumoral injection of Ad-NK4 combined with weekly GEM treatment significantly reduced growth, angiogenesis, and metastasis of human pancreatic cancer cells orthotopically implanted into nude mice.
Materials and methods

Construction of recombinant adenovirus
A recombinant adenoviral vector expressing human NK4 was constructed as described previously. 20 In brief, the vector was generated by homologous recombination of the pJM17 plasmid 21 and shuttle plasmid vector pSV2 þ 22 containing an expression cassette with the cytomegalovirus early promoter/enhancer, followed by human NK4 cDNA 17 and a polyadenylation signal. A control vector expressing bacterial b-galactosidase (LacZ) was constructed by the same procedure with pJM17 and pCA17 containing the LacZ gene. Recombinant adenovirus (denoted Ad-NK4 or Ad-LacZ) was propagated in HEK 293 cells and was purified by CsCl gradient centrifugation. Adenovirus titer in plaque-forming units (pfu) was determined by plaque formation assays with HEK 293 cells. The multiplicity of infection (MOI) was defined as the ratio of the total number of pfus used in a particular infection to the total number of cells to be infected.
Cell culture and materials
Human pancreatic cancer cell lines used in this study: PaCa-2 cells provided by the Japanese Cancer Research Resources Bank (Tokyo, Japan), and KP-2, Panc-1, and SUIT-2 cells generously donated by Dr Haruo Iguchi (National Kyushu Cancer Center, Fukuoka, Japan). Cells were cultured in RPMI medium supplemented with streptomycin (100 mg/ml), penicillin (100 units/ml), and 10% fetal bovine serum (FBS) at 371C in a humidified 90% air and 10% CO 2 environment. Total cell numbers were quantified with a particle distribution counter (CDA 500; Sysmex, Kobe, Japan). GEM (2 0 ,2 0 -difluorodeoxycytidine) was kindly provided by Eli Lilly and Company (Indianapolis, IN). GEM was dissolved in phosphatebuffered saline (PBS) and added to cell cultures or injected peritumorally into nude mice at the indicated concentrations.
Quantitative analysis of c-Met receptor mRNA levels in human pancreatic cancer cell lines by reverse-transcription (RT) PCR Total RNA was extracted from cultured cells with the High Pure RNA Isolation Kit (Roche Diagnostics, Mannheim, Germany) with DNase I (Roche Diagnostics) treatment according to the manufacturer's instructions. We designed specific primers for c-Met (forward primer, tgatgatgaggtggacaca; reverse primer, ctatggcaaggagcaaaga) and beta-actin (forward primer, aaatctggcaccacaccttc; reverse primer, ggggtgttgaaggtctcaaa), performed BLAST searches to ensure primer specificity, and performed RT-PCR with a QuantiTect SYBR Green RT-PCR Kit (QIAGEN, Tokyo, Japan) according to the manufacturer's instructions. In brief, the total volume of the reaction mixture was 20 ml and contained 10 ml 2 Â SYBR Green Buffer, 0.2 ml RT Mix, 1 ml each primer (10 mM), and 1 ml total RNA (0.01 mg/ml). The reaction mixture was first incubated at 501C for 15 min to allow for RT. PCR was then initiated at 951C for 10 min to activate modified Taq polymerase, followed by a 45-cycle amplification (951C for 15 s, 551C for 20 s, and 721C for 10 s) and one cycle (951C for 0 s, 651C for 15 s, and 0.11C/s to 951C) for melting analysis. For relative quantification, the expression of the c-Met gene was normalized to that of the beta-actin housekeeping gene and expressed as the ratio of relative expression of c-Met mRNA to that of beta-actin mRNA.
Cell proliferation assay Cell proliferation was evaluated by measuring the fluorescence intensity of propidium iodide (PI) as described previously. 23 Pancreatic cancer cells, seeded in 90-mm dishes at a density of 1 Â 10 6 cells per dish, were infected with Ad-NK4 or Ad-LacZ in 6 ml of medium at 371C for 1 h, after which the medium was replaced. After 24 h, parental cells or Ad-NK4-or Ad-LacZ-infected pancreatic cancer cells were plated at 2 Â 10 4 cells/well in 24-well tissue culture plates (Becton Dickinson Labware, Bedford, MA) and cultured for 24 h. After determination of initial cell numbers by PI assay, infected or noninfected pancreatic cancer cells were further cultured in the presence or absence of GEM at the indicated concentrations for 72 h. PI (30 mM) and digitonin (600 mM) were added to each well to label all nuclei with PI. Fluorescence intensity, corresponding to total cells, was measured by a CytoFluor II multi-well plate reader (PerSeptive Biosystems Inc., Framingham, MA) with 530-nm excitation and 645-nm emission filters. Cell proliferation was defined as the ratio of fluorescence intensity at this point to that measured at the beginning of the experiment. All experiments were performed in triplicate wells and were repeated at least three times. . GEM was added to the outer cup at concentrations ranging from 1.0 to 100 nM. HGF (10 ng/ml) was added to the medium in the outer cup to accelerate invasion, and the cells were incubated for 24 h. Cells that had degraded the Matrigel and invaded to the lower surface of the Matrigel-coated membrane were fixed with 70% ethanol and stained with hematoxylin and eosin; five randomly selected fields ( Â 400) were then quantified by light microscopy.
Invasion assay
Animals and orthotopic implantation of tumor cells
Female athymic nude mice (6 weeks old) (BALBc nu/nu) were obtained from Japan SLC (Hamamatsu, Japan). The mice were housed in laminar-flow cabinets under specific pathogen-free conditions in facilities approved by Kyushu University. SUIT-2 cells were briefly treated with trypsin-EDTA and washed twice with serum-free medium. Cell suspensions of 1 Â 10 6 cells/0.1 ml were injected into the pancreas tail of mice under anesthesia. To prevent leakage of intrapancreatic tumor cells, a cotton swab was held over the injection site for 1 min. All mice tolerated the surgical procedure well.
NK4 expression in various tissues after peritumoral injection of Ad-NK4
To evaluate NK4 expression in abdominal tissues, three mice subjected to peritumoral injection of Ad-NK4 at 5 Â 10 8 pfu/0.2 ml 5 days after orthotopic implantation were killed 5 days after viral injection. Tissue samples of pancreas including implanted tumor, liver, and spleen were homogenized in ice-cold lysis buffer consisting of 1% Triton X-100, 10 mM Tris-HCl, 5 mM EDTA, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM sodium fluoride, 0.1 mM sodium orthovanadate, and 0.1% bovine albumin. Supernatants were collected after centrifugation at 12 000 r.p.m. for 10 min. Expression of NK4 was assayed by enzyme-linked immunosorbent assay (ELISA) with a human HGF ELISA kit (Immunis HGF EIA; Institute of Immunology, Tokyo, Japan) according to the manufacturer's protocol.
Treatment with Ad-NK4 in combination with GEM Ad-LacZ or Ad-NK4 at 5 Â 10 8 pfu/0.2 ml was injected into the peritumoral region of the pancreas 5 days after orthotopic implantation. At 2 days after injection of Ad-LacZ or Ad-NK4, mice were treated weekly with i.p. administration of GEM or PBS for 3 weeks. All mice were killed when one mouse became moribund at approximately 4 weeks, and body weights were determined. Pancreas were excised and weighed. The volume of primary pancreatic tumors and the incidence of peritoneal dissemination and liver metastasis were evaluated. Pancreatic tumor diameter was measured with calipers. Pancreatic tumor volume was then calculated according to the following formula: tumor volume ¼ ab 2 /2, where a is the longest diameter of the tumor, and b is the shortest diameter. Tissue samples of the pancreatic tumors were subjected to histologic and immunohistochemical analyses. In another experiment, 40 mice (10 per group) were analyzed with respect to survival.
Immunohistochemical staining and cell counting
To stain microvessels, the peroxidase-conjugated avidinbiotin complex method was used with a Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA). Mouse monoclonal CD31 antibody JC/70A (NeoMarkers, Fremont, CA) was used at a dilution of 1:50 followed by application of biotinylated antimouse IgG (1:100; Vector Laboratories). Microvessel density (MVD) was assessed in tumor areas showing high-density staining. The number of vessels was counted in 10 fields/section; one field was magnified 200-fold (0.739 mm 2 /field), and the mean counts were recorded. Proliferating cells were detected with antibody against PCNA (PC10; DAKO Cytomation Denmark A/S, Glostrup, Denmark). To quantify PCNA staining in the tumors, the number of positive cells was counted in 10 random fields/section at Â 200. Apoptotic cells within tumor nodules were detected by TUNEL assay (In Situ Apoptosis Detection Kit; Takara, Shiga, Japan). The number of positive cells was counted in 10 random fields/section at Â 200.
Statistical analysis
Statistical significance was evaluated by Mann-Whitney U nonparametric test. Po0.05 based on a two-tailed test was considered to indicate statistical significance. Survival was analyzed by log-rank analysis of Kaplan-Meier curves. Antiproliferative effect of Ad-NK4 and/or GEM in vitro We first determined the effect of Ad-NK4 or GEM on cell proliferation in vitro with SUIT-2 cells expressing a high level of c-Met mRNA (Figure 1 ). Untreated SUIT-2 cell number increased 9-11-fold in 72 h. Infection with Ad-NK4 or Ad-LacZ did not show any antiproliferative effect at MOIs ranging from 1 to 100 (Figure 1a ). In contrast, proliferation was inhibited by GEM in a concentration-dependent manner, and 100 nM GEM completely inhibited proliferation (Figure 1b) . Simultaneous treatment with Ad-NK4 or Ad-LacZ at 50 MOI plus 100 nM GEM did not show any additive effect on cell proliferation inhibition induced by GEM, indicating that the antiproliferative effect was induced by GEM alone. Similar results were obtained with other cell lines; Ad-NK4 did not show any antiproliferation effect, but GEM inhibited the growth of Panc-1, KP-2, and PaCa-2 cells (Figure 1c ).
Inhibition of cell invasion by Ad-NK4 and/or GEM
To investigate the effect of Ad-NK4 and/or GEM on cell invasion, Ad-NK4-or Ad-LacZ-infected SUIT-2 cells or parental cells were cultured in Matrigel invasion chambers in the absence or presence of GEM at concentrations ranging from 1 to 100 nM ( Figure 2 ). The number of invading cells was not affected by infection with Ad-LacZ. In the absence of pretreatment with Ad-NK4, the number of SUIT-2 cells penetrating the Matrigel membrane was moderately decreased by GEM in a concentration-dependent manner (Figure 2a) , and 100 nM GEM inhibited invasion by 50% (Figure 2b ). The decreased number of invading cells appeared to parallel the decreased cell proliferation induced by GEM. However, it is noteworthy that 50% of the cells maintained invasive capacity after exposure to 100 nM GEM, a concentration that completely inhibited cell proliferation. The number of invading SUIT-2 cells was decreased by 50% in response to infection with Ad-NK4 at 50 MOI. In the presence of GEM, invading Ad-NK4-infected cells decreased in a concentration-dependent manner, and treatment with Ad-NK4 plus 100 nM GEM inhibited invasion by 90%. The effects of Ad-NK4 and/or GEM on cell invasion were also examined in the other cell lines; GEM showed very minor effects (Figure 2c ). In KP-2 and Panc1 cells, which showed moderate c-Met mRNA expression. Ad-NK4 inhibited invasion by 44 and 70%, respectively. Ad-NK4 plus GEM inhibited invasion by 74 and 78%, respectively. In contrast, invasion of PaCa-2 cells, which showed low c-Met mRNA expression, were not inhibited by Ad-NK4. Combined treatment with Ad-NK4 and GEM showed the strongest inhibitory effects on invasion in all three cell lines. These in vitro results indicate that only combined treatment with Ad-NK4 plus GEM inhibits both cell proliferation and cell invasion. Combined Ad-NK4 and GEM for pancreatic cancer Y Ogura et al NK4 expression in nude mice after peritumoral injection of Ad-NK4 Peritumoral injection of Ad-NK4 induced extremely high expression of NK4 in the pancreas of nude mice. NK4 expression in the pancreas and including the implanted tumor was 63.5718.6 mg/g protein 5 days after viral injection, but NK4 expression in the liver or spleen was undetectable by ELISA. These results indicate that sufficient transduction of NK4 was introduced only in the peritumoral region of the pancreas.
Inhibition of growth and metastasis of human pancreatic carcinoma implanted into the pancreas of athymic nude mice The therapeutic efficacy of Ad-NK4 plus GEM was confirmed in an orthotopic model of pancreatic cancer in athymic nude mice. First, the therapeutic effect of GEM alone was evaluated. At 7 days after implantation of tumor cells, six mice per group were treated weekly with 20, 40, 80, 160, or 320 mg/kg GEM by i.p. administration for 3 weeks, resulting in 30, 58, 75, 75, and 82% growth inhibition of SUIT-2 tumors, respectively, compared to that of untreated mice 4 weeks after implantation. Because X80 mg/kg GEM showed the same degree of growth inhibition, 80 mg/kg concentration was used exclusively thereafter. Next, mice were randomly assigned to treatment groups (n ¼ 10 each). Mice in the Ad-NK4 group were treated with Ad-NK4 by injection into the peritumoral region of the pancreas followed by weekly i.p. injection of PBS for 3 weeks. Mice in the GEM group were treated with Ad-LacZ followed by weekly i.p. injection of GEM. Mice in the Ad-NK4 plus GEM group were treated with Ad-NK4 followed by weekly i.p. injection of GEM. Control mice were treated with Ad-LacZ followed by weekly i.p. injection of PBS. On day 28 after implantation, macroscopic identification of pancreatic tumors was confirmed in all groups (Figure 3) , and peritoneal dissemination was also noted in the retroperitoneum, mesenterium, and hepatic hilum in control mice. Liver metastasis was found in 40% of control mice. No treatment produced cumulative toxicity or a change in body weight (Table 1) . Pancreatic tumor volume was significantly lower in mice treated with Ad-NK4 or GEM than in control mice (Figure 4) . Moreover, tumors in mice treated with Ad-NK4 plus GEM were significantly smaller than those treated with Ad-NK4 alone (Po0.001) or GEM (Po0.001) alone. The incidence of peritoneal dissemination was decreased by treatment with Ad-NK4 or GEM, and combination therapy completely suppressed peritoneal dissemination (Figure 3b , Table 1 ). No macroscopic liver metastases were noted in mice treated with Ad-NK4, GEM, or both (Table 1) .
Histologic and immunohistochemical analyses
Histologically, primary tumors in all groups were moderately to poorly differentiated adenocarcinomas. Necrotic lesions were identified in the center of the tumor region in mice treated with GEM, Ad-NK4, or both. Tumor cell proliferation was evaluated as the percentage of PCNA-positive cells, and a significant inhibition was Prolonged survival A final experiment was carried out to determine the effect of combination therapy on survival ( Figure 6 ). Severe cancer cachexia developed in control mice approximately 4 weeks after implantation. The median survival time in the control group was 41 days. The median survival times in the GEM group (50 days) and the Ad-NK4 group (51 days) were similar, differing significantly from that of the control group (GEM versus control, Po0.05; Ad-NK4 versus control, Po0.02). The median survival time of Combined Ad-NK4 and GEM for pancreatic cancer Y Ogura et al mice treated with Ad-NK4 plus GEM was 66 days (versus GEM alone, Po0.01; versus Ad-NK4, P ¼ 0.031; versus control, Po0.001).
Discussion
We showed that peritumoral injection of Ad-NK4 in combination with GEM treatment strongly inhibited growth, peritoneal dissemination, and liver metastasis of human pancreatic cancer cells implanted into the pancreas of athymic nude mice and prolonged their survival. Combined Ad-NK4 and GEM for pancreatic cancer Y Ogura et al
In vivo analysis revealed that the significant antitumor effect of Ad-NK4 was mediated in part by inhibition of angiogenesis and that the antitumor effect of GEM was limited to its antiproliferative influence. GEM had no influence on angiogenesis. Thus, the high rate of apoptosis in combination therapy was induced by the complementary actions of the two treatments, namely antiproliferation by GEM and antiangiogenesis by NK4.
In vitro, Ad-NK4 infection potently inhibited invasion of cancer cells in response to HGF and had no effect on proliferation. GEM exerted a very limited effect on invasive ability but showed a powerful antiproliferative effect similar to that observed in the in vivo study. Therefore, the strong in vivo antitumor effect of combination therapy with Ad-NK4 plus GEM was due to inhibition of proliferation, motility, and angiogenesis. In our in vivo studies, treatment with Ad-NK4, which showed no antiproliferative effect, prevented tumor angiogenesis and subsequently increased apoptosis and prolonged survival. Strong antiangiogenic activity of NK4 in pancreatic cancer has been reported previously in our various in vivo studies of subcutaneous and orthotopic transplantation, peritoneal dissemination, and liver metastasis.
8,24-26 Saimura et al. 27 reported that an NK4 cDNA-transfected pancreatic cancer clone showed significant growth inhibition and reduced tumor vessel growth in vivo, although this clone showed an insufficient expression of NK4 to antagonize HGF. Therefore, at least in that study, the significant antitumor effect of NK4 in vivo depended mainly on its function as an angiogenesis inhibitor rather than as an HGF antagonist. NK4 inhibits growth and migration of microvascular endothelial cells stimulated by VEGF or bFGF as well as by HGF in vitro, 19 indicating that the antiangiogenic activity of NK4 is independent of its activity as an HGF antagonist. Putative binding molecules for NK4 may exist on endothelial cells, or unknown intracellular signals may interrupt VEGF/bFGFmediated angiogenesis after inhibition of c-Met phosphorylation by NK4.
Significant inhibition of tumor growth in response to combination therapy was clear compared to the antitumor effect of high-dose GEM. A high dose of GEM, 320 mg/kg, increased tumor suppression by only 7% compared to that with 80 mg/kg of GEM (from 75 to 82%). Combination treatment of Ad-NK4 plus 80 mg/kg GEM compared to treatment with GEM alone suppressed tumor growth by 16% (from 75 to 91%) without increased toxicity. These results clearly indicate the efficient antitumor effect of combination therapy in the control of local growth of implanted tumors.
An antimetastatic effect of combination therapy may have led to prolonged survival. The most devastating aspect of pancreatic cancer is its early systemic dissemination and distant metastases; most deaths are related to metastasis. We have documented that antiangiogenic activity is important in the suppression of peritoneal dissemination. 8, 25, 27 Metastasis comprises stepwise cell attachment, angiogenesis, proliferation, and invasion, and it is important to regulate these steps. 28 NK4 interferes with invasion of cancer cells and tumor angiogenesis by means of its bifunctional properties as an HGF antagonist and an angiogenesis inhibitor. 19, 29 GEM inhibits proliferation of metastasized cells. Therefore, combination therapy inhibits three steps of tumor metastasis: angiogenesis, proliferation, and invasion. As a result, combination therapy completely suppressed both peritoneal dissemination and liver metastasis, resulting in prolonged survival.
Clinical trials of GEM combined with several antitumor agents have been conducted for pancreatic cancer. 30 However, the majority of these therapies used cytotoxic drugs, such as docetaxel, 5FU, cisplatin, and irinotecan. [31] [32] [33] [34] [35] Although these cytotoxic drugs exert antitumor effects by different mechanisms, the applicable dose of each drug is limited due to cumulative systemic toxicity. In such clinical trials, combination therapy may result in more adverse effects despite the expected additive antitumor effects. Because of the lack of an antiproliferative effect of NK4 on normal cells as well as cancer cells, the toxicity of combination therapy of Ad-NK4 plus GEM should be minimized. In fact, as shown in the present study, combination of sufficient doses of a cytotoxic agent, GEM, plus Ad-NK4 provided maximum antitumor effects without escalating toxicity.
Cancer gene therapy is generally at a stage of proof of principles and safety. In considering clinical trials of Ad-NK4 for pancreatic cancer, it is important to inject Ad-NK4 into the tumor mass instead of delivering it systemically because a large amount of NK4 protein delivered to the tumor is necessary for complete inhibition of HGF activity and for significant suppression of tumor growth. Clinical trials of gene therapy plus GEM treatment have been reported, for example, with conditionally replicating adenovirus (ONYX-015) or adenovirus encoding interleukin-12 injected into the tumor under endoscopic ultrasonographic (EUS) control. 36, 37 In these studies, severe complications, including pancreatitis, did not occur. Peritumoral injection of Ad-NK4 under EUS control in combination with GEM would be safe and effective for patients with advanced pancreatic cancer.
In summary, we showed that peritumoral injection of Ad-NK4 combined with weekly GEM treatment significantly reduced growth and metastasis of human pancreatic cancer cells implanted orthotopically into nude mice and prolonged survival of the mice. Inhibition of primary tumor growth, liver metastasis, and peritoneal dissemination was mediated by the bifunctional effects of NK4 as an HGF antagonist and an angiogenesis inhibitor and by the direct antitumor effect of GEM. Clinical trials to assess the safety and validity of Ad-NK4 in combination with GEM are warranted in patients with pancreatic cancer.
